

Special Issue

New Approaches in Modulating Transcription Factors for Cancer Therapy: 2nd Edition

Message from the Guest Editor

This collection is the second edition of the previous one entitled "[New Approaches in Modulating Transcription Factors for Cancer Therapy](#)". Aberrant expression or activation of transcription factors occurs in most cancers. Transcription factors are often the convergence point from many upstream signals that may be mutated or overexpressed in cancer, leading to inappropriate expression or constitutive activation. These transcription factors often promote the pathogenic features of cancer, and most cancers become addicted to the constitutive activity of the transcription factor. However, most transcription factors are often difficult to target, since many of them lack a ligand binding or active site. In this Special Issue, we will focus on new treatment modalities that target transcription factors in cancer. These strategies may include new small molecule inhibitors, CRISPR-based strategies, degrader technology, peptide mimetics, or others.

Guest Editor

Dr. Sarah Walker

Department of Molecular, Cellular, and Biomedical Sciences, University of New Hampshire, Durham, NH 03824, USA

Deadline for manuscript submissions

30 November 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/222454

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)